6,675,000 grams proposed, medical quotas deferred

Federal drug regulators have proposed a 2027 production limit of 6,675,000 grams for marijuana in Schedule I, a federal drug category subject to strict production controls. The figure excludes the separate medical-marijuana categories moved into Schedule III earlier this year. That less restrictive classification still carries production controls of its own.

The Drug Enforcement Administration's November 10 notice leaves those medical quantities for a separate publication. With producers approaching the next calendar year, the distinction matters: the published number cannot tell qualifying medical businesses how much production the federal government will allow for their categories in 2027.

The Schedule I amount is a proposal, not a final limit. Comments close December 10, 2026, under docket DEA-1730P, the reference number for this proceeding. As of this article's November 16 publication, the notice offers a proposed quantity for one part of the federal cannabis system while explicitly withholding quantities for another.

The proposed 6,675,000 grams matches the initial marijuana quota established for 2026 in a January 5 Federal Register notice. That is a comparison with the starting figure for 2026, not a claim that the quota remained unchanged throughout the year. It also does not establish that total federally permitted cannabis production will be flat in 2027, because the separate medical categories are missing from the comparison.

DEA says it is still evaluating the data and methods needed to determine Schedule III production requirements. This is more than an omitted table entry. The agency has not supplied the medical quantities in this notice, and its explanation indicates that the calculation behind them is still being developed.

For medical manufacturers, the immediate consequence is a planning gap, not a demonstrated supply interruption. A company considering next year's cultivation or manufacturing capacity cannot use the Schedule I figure as a substitute for the missing medical limit. Nor can a retailer treat it as a forecast of products reaching dispensary shelves.

The November notice therefore has two different meanings. For the marijuana category it covers, it opens a formal process toward a 2027 limit. For the medical categories it excludes, it confirms that a separate production decision remains ahead. Combining those meanings into a single national cannabis-capacity headline would obscure the part of the decision that medical operators still need.

The April rule changed categories, not every production control

The reason for the split is the April 28 rescheduling rule. That rule moved qualifying marijuana in Food and Drug Administration-approved products and qualifying state-licensed medical marijuana into Schedule III. It did not move all marijuana into that category, and it did not remove every federal restriction on producing the marijuana it covered.

The two covered categories depend on different conditions: FDA approval for the product category, or the state medical-marijuana licensing status specified by the rule. A state adult-use license alone does not meet the medical-license condition. Marijuana outside the two qualifying categories remains in Schedule I. A business's participation in a state cannabis market is therefore not, by itself, enough to identify which federal production framework applies.

That boundary is particularly important for companies serving both medical and adult-use customers. The existence of a medical business does not make the April rule a blanket reclassification of every marijuana activity associated with the company. The relevant distinction is the marijuana covered by the qualifying categories, rather than a broad description of the operator as a cannabis business.

The April rule also retained production controls connected to international drug-treaty obligations. In practical terms, the move to a less restrictive drug category did not eliminate the federal government's role in determining permitted production quantities. Classification and production permission answer different questions: one identifies the legal category, while the other controls how much may be manufactured under the applicable system.

The November proposal concerns an aggregate production quota. That means a nationwide production amount for a listed controlled substance within the federal system. It is not a sales estimate, a state-by-state cultivation allowance or a quantity assigned to an individual company. A proposed aggregate quota is also not permission for a producer to begin manufacturing that amount.

DEA's guidance for federally registered Schedule I marijuana growers illustrates the next layer. Those growers apply for individual manufacturing quotas and provide supporting supply agreements. The individual quota concerns a particular manufacturer's permitted production, while the aggregate quota concerns the overall amount. Registration, a national production figure and a company's own allocation are distinct parts of that system.

That guidance provides useful background, but it does not establish the operating instructions for the developing Schedule III medical framework. The specific Schedule I application and supply-agreement procedures cannot simply be carried across to medical producers without confirmation. The separate medical notice matters both for the quantity it may propose and for what it explains about the framework surrounding that quantity.

This is why rescheduling alone cannot settle a capacity plan. A business may fall within a newly covered medical category while still needing clarity about the production controls attached to it. The April rule changed an important legal boundary. The November notice shows that determining the quantities on the medical side of that boundary is a separate task.

Missing medical quantities complicate capacity planning, not prove a shortage

Production planning involves decisions that often precede a sale by months. Cultivators arrange growing space and crop schedules. Manufacturers organize equipment, staff and inputs. Suppliers plan around expected orders. For businesses within the Schedule III medical categories, an unresolved federal production quantity leaves one of the constraints on those decisions unsettled.

Consider a medical manufacturer assessing whether existing facilities will be sufficient for 2027. Expected demand and physical capacity are commercial inputs. The applicable federal production limit is a separate regulatory input. A proposed limit for Schedule I marijuana cannot fill that gap, because it measures a category from which the qualifying medical production has been excluded.

The same distinction matters to suppliers. A customer's planned expansion can indicate potential demand for equipment or services, but the November figure does not establish the customer's permitted medical output. The uncertainty concerns how commercial plans will fit within the eventual production framework. It does not establish that those plans have been cancelled, delayed or rejected.

For companies operating across medical and adult-use markets, a single consolidated production forecast can conceal this division. Business accounts may combine activities that federal rules treat differently. Reading the proposed national quota as a measure of the whole company's opportunity would ignore both the medical exclusion and the fact that an aggregate amount is not an individual allocation.

Investors face a related interpretation problem. The match with the initial 2026 quota may look like a signal of stability, but it is stability in one proposed figure against one historical starting point. It is not evidence that medical capacity will remain unchanged, that expansion will be permitted or that existing facilities will be fully used. Those conclusions require information the Schedule I number does not provide.

Retailers and patients are further removed from the quota-setting process, but they are vulnerable to an overly broad reading of the headline. A production quota expressed in grams is not a count of finished products available at particular dispensaries. Manufacturing, inventory and distribution stand between permission to produce and a purchase. The published figure alone says nothing about where or when a particular product will be available.

Researchers working with federally registered Schedule I growers face a different set of planning questions from medical-market manufacturers. The proposed Schedule I aggregate is relevant to that federal supply framework, but an individual project's access still cannot be read directly from the national total. DEA's grower guidance makes the distinction between the aggregate amount and manufacturer-level arrangements particularly clear.

None of this establishes an imminent shortage. The absence of medical quantities in the November notice is evidence of an unfinished regulatory calculation, not evidence that patients are about to lose access or that producers are running out of stock. The defensible industry concern is narrower: businesses approaching 2027 still lack a published medical-production figure in this proceeding against which to assess their plans.

The separate medical notice must explain more than a number

The next medical-quota notice will need to make its proposed quantities understandable, not merely publish them. DEA's statement that it is evaluating data and methods puts the basis of the calculation at the center of the unresolved issue. A production figure is useful only when its scope is clear enough to distinguish a real constraint from a number that belongs to a different category.

For that reason, the treatment of the two medical categories will matter. FDA-approved products and marijuana qualifying through state medical licensing enter the framework on different grounds. A useful notice would make clear which production is counted in each relevant amount and how the categories relate to the national totals. Otherwise, even a precise figure could be misread as covering more or less of the market than it does.

The explanation of demand will matter as well. A quota is a government production determination, not simply the sum of companies' growth ambitions. An account of the data used to estimate medical requirements, and the treatment of existing supply, would allow readers to understand what the proposed amount is designed to cover. The November notice's deferral leaves that assessment for the medical proceeding.

The connection between national quantities and producer-level permission is another essential distinction. DEA's existing Schedule I guidance shows why an aggregate figure alone cannot answer every manufacturer's question. The medical framework needs to be explained on its own terms rather than inferred from procedures written for a different category. That is an issue of operational clarity, not a demand that every company receive its preferred allocation.

The December 10 comment deadline does not close these gaps. It applies to the proposal already published. It should not be mistaken for the date on which medical producers gain access to a settled production allowance. Likewise, finalizing the proposed Schedule I quota would not, by itself, supply the separate medical quantities that this notice excludes.

There is a legitimate distinction between taking time to build a defensible calculation and leaving businesses without a usable planning framework. The notice establishes the former as DEA's stated work. The approach of 2027 makes the latter a practical concern. Both can be true without implying that a supply crisis is underway.

The government's task is not to guarantee that every expansion plan can proceed. It is to make the production constraint clear enough that a company can distinguish a commercial risk from a regulatory unknown. For the medical categories, that standard will be met by an explained and usable framework, not by borrowing certainty from a Schedule I number that does not cover them.